Can mGluR5 antagonists be utilized to reduce beta-amyloid levels in Alzheimer’s disease and other neurological disorders

Cara J. Westmark
University of Wisconsin, USA

Messenger RNA (mRNA) binding proteins, which modulate ribosomal access and initiation, regulate dendritic translation. One of the best-known examples is the fragile X mental retardation protein (FMRP), which represses the translation of a subset of dendritic mRNAs whose products affect synaptic plasticity and function. Metabotropic glutamate receptor 5 (mGluR5) signaling causes pulsatile translation of post-synaptic mRNAs by repressing FMRP. We have demonstrated that FMRP binds to and controls the post-synaptic translation of amyloid-beta protein precursor (APP) mRNA and that mGluR5 signaling increases APP production. APP is cleaved to beta-amyloid, the predominant protein in the senile plaques in Alzheimer’s disease (AD) and Down syndrome. Chronic treatment with the mGluR5 inhibitor fenobam reduces beta-amyloid levels in AD mice. APP and beta-amyloid are also up-regulated in a mouse model for Fragile X syndrome (FXS), a disorder characterized by lack of expression of FMRP. mGluR5 antagonists are under intense investigation as a possible therapeutic treatment for FXS. We hypothesize that mGluR5 antagonists improve FXS phenotypes by modulating APP and beta-amyloid levels and that these inhibitors are potential therapeutics for AD and DS as well. There is currently a dearth of potent therapeutics for beta-amyloid reduction, and the mGluR5 antagonist fenobam has been previously approved for phase I and II clinical trials in humans. Thus, this drug could be rapidly extrapolated to humans.